Back to Search
Start Over
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
- Source :
-
American journal of medical genetics. Part A [Am J Med Genet A] 2019 Jun; Vol. 179 (6), pp. 1069-1073. Date of Electronic Publication: 2019 Mar 28. - Publication Year :
- 2019
- Subjects :
- 1-Deoxynojirimycin administration & dosage
1-Deoxynojirimycin adverse effects
1-Deoxynojirimycin therapeutic use
Drug Substitution
Enzyme Replacement Therapy methods
Fabry Disease diagnosis
Fabry Disease genetics
Fabry Disease metabolism
Female
Humans
Male
alpha-Galactosidase administration & dosage
alpha-Galactosidase therapeutic use
1-Deoxynojirimycin analogs & derivatives
Fabry Disease therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1552-4833
- Volume :
- 179
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- American journal of medical genetics. Part A
- Publication Type :
- Report
- Accession number :
- 30920142
- Full Text :
- https://doi.org/10.1002/ajmg.a.61105